Donders Institute for Brain, Cognition and Behaviour, Department of Neurosurgery, Radboud University Medical Center, Nijmegen, The Netherlands.
Department of Neurology, University Medical Center Ljubljana, Ljubljana, Slovenia.
J Parkinsons Dis. 2022;12(4):1269-1278. doi: 10.3233/JPD-223149.
Bilateral deep brain stimulation of the subthalamic nucleus (STN-DBS) has become a cornerstone in the advanced treatment of Parkinson's disease (PD). Despite its well-established clinical benefit, there is a significant variation in the way surgery is performed. Most centers operate with the patient awake to allow for microelectrode recording (MER) and intraoperative clinical testing. However, technical advances in MR imaging and MRI-guided surgery raise the question whether MER and intraoperative clinical testing still have added value in DBS-surgery.
To evaluate the added value of MER and intraoperative clinical testing to determine final lead position in awake MRI-guided and stereotactic CT-verified STN-DBS surgery for PD.
29 consecutive patients were analyzed retrospectively. Patients underwent awake bilateral STN-DBS with MER and intraoperative clinical testing. The role of MER and clinical testing in determining final lead position was evaluated. Furthermore, interobserver variability in determining the MRI-defined STN along the planned trajectory was investigated. Clinical improvement was evaluated at 12 months follow-up and adverse events were recorded.
98% of final leads were placed in the central MER-track with an accuracy of 0.88±0.45 mm. Interobserver variability of the MRI-defined STN was 0.84±0.09. Compared to baseline, mean improvement in MDS-UPDRS-III, PDQ-39 and LEDD were 26.7±16.0 points (54%) (p < 0.001), 9.0±20.0 points (19%) (p = 0.025), and 794±434 mg/day (59%) (p < 0.001) respectively. There were 19 adverse events in 11 patients, one of which (lead malposition requiring immediate postoperative revision) was a serious adverse event.
MER and intraoperative clinical testing had no additional value in determining final lead position. These results changed our daily clinical practice to an asleep MRI-guided and stereotactic CT-verified approach.
双侧丘脑底核(STN)深部脑刺激(DBS)已成为治疗帕金森病(PD)的重要手段。尽管其临床疗效已得到广泛证实,但手术方式仍存在较大差异。大多数中心采用患者清醒状态下进行手术,以实现微电极记录(MER)和术中临床测试。然而,磁共振成像(MRI)和 MRI 引导手术技术的进步提出了一个问题,即在 DBS 手术中,MER 和术中临床测试是否仍然具有附加价值。
评估 MER 和术中临床测试在确定清醒 MRI 引导和立体定向 CT 验证的 PD 患者双侧 STN-DBS 手术中最终导联位置的附加价值。
回顾性分析 29 例连续患者。患者接受双侧 STN-DBS 手术,术中进行 MER 和临床测试。评估 MER 和临床测试在确定最终导联位置中的作用。此外,还研究了在计划轨迹上确定 MRI 定义的 STN 时的观察者间变异性。在 12 个月的随访中评估临床改善情况,并记录不良事件。
98%的最终导联放置在中央 MER 轨迹内,准确性为 0.88±0.45mm。MRI 定义的 STN 的观察者间变异性为 0.84±0.09。与基线相比,MDS-UPDRS-III、PDQ-39 和 LEDD 的平均改善分别为 26.7±16.0 分(54%)(p<0.001)、9.0±20.0 分(19%)(p=0.025)和 794±434mg/天(59%)(p<0.001)。11 例患者中有 19 例出现 19 例不良事件,其中 1 例(因导联位置不良需立即术后修正)为严重不良事件。
MER 和术中临床测试在确定最终导联位置方面没有额外价值。这些结果改变了我们的日常临床实践,采用了在睡眠状态下进行 MRI 引导和立体定向 CT 验证的方法。